PDCD1 and lung carcinoma: Chen et al. demonstrated that pembrolizumab (PD-1)-activated autologous DC-CIK cells exhibited a promising safety profile and showed an encouraging clinical response in patients with advanced solid tumors, including lung cancer [18].